prikaz prve stranice dokumenta Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji
  Download
PDF 389.53 KB
master's thesis
Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji
2017. urn:nbn:hr:171:461978
Vuković, Antonija
University of Split
School of Medicine

Cite this document

Vuković, A. (2017). Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:461978

Vuković, Antonija. "Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji." Master's thesis, University of Split, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:171:461978

Vuković, Antonija. "Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji." Master's thesis, University of Split, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:171:461978

Vuković, A. (2017). 'Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji', Master's thesis, University of Split, School of Medicine, accessed 05 April 2025, https://urn.nsk.hr/urn:nbn:hr:171:461978

Vuković A. Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji [Master's thesis]. Split: University of Split, School of Medicine; 2017 [cited 2025 April 05] Available at: https://urn.nsk.hr/urn:nbn:hr:171:461978

A. Vuković, "Učestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji", Master's thesis, University of Split, School of Medicine, Split, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:171:461978

Please login to the repository to save this object to your list.
Metadata
TitleUčestalost malignoma u bolesnika sa sistemskim eritemskim lupusom u Splitsko-dalmatinskoj županiji
Title (english)Incidence of malignoma in patients with systemic lupus erythematosus in Split-Dalmatia County during a ten-year period
AuthorAntonija Vuković
MentorDijana Perković (mentor)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2017, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
CILJ ISTRAŽIVANJA: Cilj ovog istraživanja bio je utvrditi učestalost i klinička obilježja malignih oboljenja u bolesnika sa SLE-om u Splitsko-dalmatinskoj županiji u desetogodišnjem periodu. MATERIJALI I METODE: Istraživanje je obuhvatilo 271 bolesnika sa SLE-om liječenih u KBC-u Split u razdobolju od 1. siječnja 2007. do 31. prosinca 2016. godine. Za dobivanje podataka korištena je medicinska dokumentacija iz ambulante, stacionara i dnevne bolnice Zavoda za kliničku imunologiju i... More reumatologiju. Bolesnici su uključeni u istraživanje na temlju jasne dijagnoze SLE-a prema revidiranim ACR kriterijima. REZULTATI: U skupini od 271 bolesnika maligno oboljenje se javilo kod njih 24 (8,85%). Sveukupno je pronađeno 27 malignih tumora jer su neki bolesnici imali više od jednog tumora. Od ukupnog broja bolesnika 26 je bilo muškog spola (9,59%) i 245 ženskog spola (90,41%), a od bolesnika s malignim oboljenjem 3 su bila muškarca (12,50%) i 21žena (87,50%). Prosječna dob bolesnika sa SLE-om je 49,45 godina, a bolesnika sa SLE-om i malignim oboljenjem 60,2 godine. Šestoro bolesnika iz skupine s malignim oboljenjima je preminulo, jedno od posljedica malignoma, a dvoje nevezano za malignom, a za troje je uzrok nepoznat. Većina bolesnika (79,17%) je oboljela od malignog tumora nakon postavljanja dijagnoze SLE-a. Najčešća lokalizacija malignoma bio je grlić maternice (25%). Većina bolesnika s malignim oboljenjem je ANA (79,17%) i ENA (79,17%) pozitivno. Bolesnici s malignomom su najčešće bili na terapiji kortikosteroidima (54,16%), potom kombinaciji kortikosteroida i imunosupresiva (29,16%), zatim bez kortikosteroida i imunosupresiva (16,66%), a ni jedan bolesnik nije bio isključivo na terapiji imunosupresivima. ZAKLJUČAK: Maligno oboljenje se javilo u 8,85% bolesnika s dijagnozom SLE-a. Bolesnici s malignim oboljenjem u sklopu SLE-a su statistički značajno stariji od bolesnika bez malignog oboljenja. Najčešća lokalizacija malignoma bio je grlić maternice (25%). Statistički značajna većina bolesnika s malignim oboljenjem i SLE-om je ANA i ENA pozitivna. Less
Abstract (english)
OBJECTIVES: The aim of this study was to determine the incidence of malignant neoplasms in patients with systemic lupus erythematosus and their clinical features in Split-Dalmatia county during a ten-year period. METHODS: 271 patients with SLE were included in this study, all of them being treated in University Hospital Split during the period from January 1, 2007. to December 31, 2016. The data was collected from the archives of the Department of Clinical Immunology and... More Rheumatology. All patients were evaluated by the revised ACR criteria for SLE. RESULTS: In the group of 271 patients, 24 of them developed a malignant neoplasm (8,85%). We found 27 malignant neoplasms due to the fact that some patients had had more than one tumor. Looking at the total number of 271 patients, 26 of them were male (9,59%) and 245 were women (90,41%) and when we focus on the group with malignomas there were 3 male patients (12,50%) and 21 female patients (87,50%). The average age for patients with SLE and without malignoma was 49,45 years and for the group with malignoma 60,2 years. Three patients from the malignoma group died during this period, one due to malignancy and two because of other medical conditions not connected to malignancy. Most patients developed malignoma after the diagnosis of SLE (79,17%). The most common localisation for malignant neoplasms was the cervix (25%). Most of the patients in the malignoma group were ANA (79,17%) and ENA (79,17%) positive. Those patients were most commonly on a corticosteroid therapy (54,16%), followed by combination of corticosteroids and immunosuppressive therapy (29,16%) and no use of corticosteroid or immunosuppressive therapy (16,66%). None of the patients were taking only immunosuppressive therapy. CONCLUSION: Malignancy occured in 8,85% of the patients with SLE. Patients suffering from SLE and a malignant neoplasms were statistically significantly older than the patients suffering only from SLE. The most common localisation of malignoma was the cervix (25%). Statistically significant majority of patients with malignoma and SLE were ANA and ENA positive. Less
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:461978
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-11-16 10:25:02
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.